SEC Form	n 4																		
FORM 4 UNI				TED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									Estima			Number: 3235-0287 hated average burden s per response: 0.5		
1. Name and Address of Reporting Person* REICIN ALISE					2. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [SANA]								ck all applica	able)	10% Own				
(Last) (First) (Middle) C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 02/03/2021								officer (below)	(give title		Other (sp below)	lecity		
(Street) SEATTLE WA 98102					4. If Amendment, Date of Original Filed (Month/Day/Year) 02/05/2021								Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)							<u> </u>									
Date				2. Transac	action 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		Securit sposed	ties Acquired (A) or d Of (D) (Instr. 3, 4 and 5)		5. Amount of		Form: Direct		Nature of direct eneficial wnership nstr. 4)		
										nount	(D)	Price	(Instr. 3 a	nstr. 3 and 4)					
			Table II - D (e					uired, Di s, options					Dwned						
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	Date	of Securities		ies g Derivative	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e S Ily I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	of	(Instr. 4)					
Stock Option (Right to Buy)	\$25	02/03/2021		A		11,795 ⁽¹⁾		(2)	02/02	2/2031	Common Stock	11 ,79 5 ⁽¹⁾	\$0.00	11,795 ⁽	(1)	D			

Explanation of Responses:

1. This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired.

2. The stock option shall vest and become exercisable in full on February 3, 2022.

Remarks:

<u>/s/ James J. MacDonald,</u> <u>Attorney-in-Fact for Alise</u> Reicin

02/18/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.